Effect of parenteral L-carnitine in hospitalized patients with moderate to severe COVID-19: A randomized double-blind clinical trial

Author:

Naeimzadeh Farnaz12ORCID,Sadeghi Armin3ORCID,Saghaleini Seiedhadi4ORCID,Sarbakhsh Parvin5ORCID,Mahmoodpoor Ata64ORCID,Gharekhani Afshin72ORCID

Affiliation:

1. Student Research Committee, Tabriz University of Medical Sciences, Iran

2. Department of Clinical Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

3. Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, ‎Tabriz, Iran

4. Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, Iran

5. Department of Statistics and Epidemiology, Faculty of Public Health, Tabriz University of ‎Medical Sciences, Tabriz, Iran

6. Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University ‎of Medical Sciences, Tabriz, Iran

7. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, ‎Tabriz, Iran

Abstract

Introduction: Pro-inflammatory responses have an important role in developing coronavirus disease 2019 (COVID-19). L-carnitine (LC) has been known to possess anti-inflammatory, anticoagulant, and antiviral effects. So, we aimed to evaluate the efficacy of LC in hospitalized patients with moderate-to-severe COVID-19. Methods: This double-blind, placebo-controlled, randomized clinical trial was conducted on hospitalized patients with moderate to severe COVID-19. The patients were randomized (1:1) to receive LC (n = 50) at a dose of 20 mg/kg or matching placebo (n = 51) from normal saline once daily for 14 days or until hospitalization and standard care. The primary outcome was hospital mortality and disease severity according to the World Health Organization's clinical progression scale. We also assessed the free carnitine level at baseline and the end of the study. C-reactive protein (CRP), ferritin, D-dimer, lactate dehydrogenase (LDH), and improvement of respiratory conditions were chosen as secondary outcomes Results: From 104 patients who met the inclusion criteria, 101 individuals’ data were analyzed. The LC group showed a significant reduction in LDH levels (P = 0.003), although CRP, ferritin, and D-dimer levels did not significantly differ from the placebo group. Also, no significant difference was observed in disease severity, oxygenation status, hospital mortality, or hospital stay between the two groups. Additionally, there was no increase in serum-free carnitine levels in the LC group (P > 0.05 for all). Conclusion: The results of the current study did not support the superiority of LC over placebo in improving oxygenation, decreasing mortality, and hospital stay, as well as CRP, ferritin, and D-dimer in moderate to severe COVID-19 patients. Trial Registration: IRCT20170609034406N10; https://en.irct.ir/trial/60306.

Publisher

Maad Rayan Publishing Company

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3